BioCatalystWatch
ELTXWorkspace / ELTX / OverviewCompany library
Elicio Therapeutics, Inc. logo

Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. (ELTX)

Website

Price
Market cap
Next catalystExpected Q4 2026Camupepimut + daraxonrasib, with or without nivolumab — planned metastatic PDAC study · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

camupepimut

KRAS G12D × KRAS G12R × KRAS G12V × KRAS G12C × KRAS G12A × KRAS G12S × KRAS G13D

PreINDP1P2P3FilingApproved

camupepimutCamupepimut + daraxonrasib, with or without nivolumab — planned metastatic PDAC study

KRAS G12D × KRAS G12R × KRAS G12V × KRAS G12C × KRAS G12A × KRAS G12S × KRAS G13D

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

camupepimutCamupepimut + daraxonrasib, with or without nivolumab — planned metastatic PDAC study

KRAS G12D × KRAS G12R × KRAS G12V × KRAS G12C × KRAS G12A × KRAS G12S × KRAS G13D

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

camupepimut

KRAS G12D × KRAS G12R × KRAS G12V × KRAS G12C × KRAS G12A × KRAS G12S × KRAS G13D

PreINDP1P2P3FilingApproved

Other pipelines

TLR9

camupepimut

KRAS G12D × KRAS G12R × KRAS G12V × KRAS G12C × KRAS G12A × KRAS G12S × KRAS G13D

ELI-008

mutant TP53 hotspot antigens

PreINDP1P2P3FilingApproved
ELI-005

SARS-CoV-2 spike RBD × TLR9

PreINDP1P2P3FilingApproved
ELI-007

BRAF V600E × BRAF V600K

PreINDP1P2P3FilingApproved

Partner / License out

camupepimut

KRAS G12D × KRAS G12R × KRAS G12V × KRAS G12C × KRAS G12A × KRAS G12S × KRAS G13D

PreINDP1P2P3FilingApproved

History / paused

KRAS G12D × KRAS G12R

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ELTX PR & News

PR & News

ELTX SEC archive